

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7238562

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MEDIMMUNE, LLC	02/16/2022
RECEIVING PARTY DATA	
Name:	MEDIMMUNE LIMITED
Street Address:	MILSTEIN BUILDING
Internal Address:	GRANTA PARK
City:	CAMBRIDGE
State/Country:	GREAT BRITAIN
Postal Code:	CB21 6GH
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	10689437
Patent Number:	11186628
Application Number:	17451955
Application Number:	15111610
Application Number:	61927819
CORRESPONDENCE DATA	
Fax Number:	(617)646-1666
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617)646-1600
Email:	donna.studley@finnegan.com
Correspondent Name:	FINNEGAN
Address Line 1:	901 NEW YORK AVE. N.W.
Address Line 4:	WASHINGTON, D.C. 20001-4413
ATTORNEY DOCKET NUMBER:	15826.0005 ASSIGNMENT
NAME OF SUBMITTER:	SARA A. LEIMAN
SIGNATURE:	/Sara A. Leiman/
DATE SIGNED:	03/22/2022
Total Attachments: 5	

source=RSVNG-103 Assignment#page1.tif
source=RSVNG-103 Assignment#page2.tif
source=RSVNG-103 Assignment#page3.tif
source=RSVNG-103 Assignment#page4.tif
source=RSVNG-103 Assignment#page5.tif

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 15 February 2022 (the "Effective Date") by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("Assignor"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, whose registered office is Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom ("Assignee").

WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to the patent applications identified in the attached Schedule (the "Applications") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.


5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
MEDIMMUNE, LLC
Name: *Patrick Scott Alban*
Title: Authorised Signatory

Date *February 16, 2022*



Signed for and on behalf of
MEDIMMUNE LIMITED
Name: *ALISON MCGHEE*
Title: Authorised Signatory

Date *22 FEB 2022*

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Application No.	Patent No.	Filing Date
RSVNG-103-AL-EPT	Albania	15737068.5	3094353	14 Jan 2015
RSVNG-103-AT-EPT	Austria	15737068.5	3094353	14 Jan 2015
RSVNG-103-AU-PCD	Australia	2020203831		10 Jun 2020
RSVNG-103-AU-PCD[2]	Australia	2021204339		25 Jun 2021
RSVNG-103-AU-PCT	Australia	2015206570		14 Jan 2015
RSVNG-103-BE-EPT	Belgium	15737068.5	3094353	14 Jan 2015
RSVNG-103-BG-EPT	Bulgaria	15737068.5	3094353	14 Jan 2015
RSVNG-103-BR-PCT	Brazil	BR112016015044-9		14 Jan 2015
RSVNG-103-CA-PCT	Canada	2,933,200		14 Jan 2015
RSVNG-103-CH-EPT	Switzerland	15737068.5	3094353	14 Jan 2015
RSVNG-103-CN-PCT	China	201580003410.4		14 Jan 2015
RSVNG-103-CY-EPT	Cyprus	15737068.5	3094353	14 Jan 2015
RSVNG-103-CZ-EPT	Czech Republic	15737068.5	3094353	14 Jan 2015
RSVNG-103-DE-EPT	Germany	15737068.5	60 2015 049 828.3	14 Jan 2015
RSVNG-103-DK-EPT	Denmark	15737068.5	3094353	14 Jan 2015
RSVNG-103-EE-EPT	Estonia	15737068.5	3094353	14 Jan 2015
RSVNG-103-EP-EPT	European Patent Office	15737068.5	3094353	14 Jan 2015
RSVNG-103-EP-ETD	European Patent Office	20161884.0		14 Jan 2015
RSVNG-103-ES-EPT	Spain	15737068.5	300367476	14 Jan 2015
RSVNG-103-FI-EPT	Finland	15737068.5	3094353	14 Jan 2015
RSVNG-103-FR-EPT	France	15737068.5	3094353	14 Jan 2015

RSVNG-103-GB-EPT	United Kingdom	15737068.5	3094353	14 Jan 2015
RSVNG-103-GR-EPT	Greece	15737068.5	3094353	14 Jan 2015
RSVNG-103-HK-FPR	Hong Kong	16114507.9	HK1225992	21 Dec 2016
RSVNG-103-HK-FPR[2]	Hong Kong	42021031648.5		24 May 2021
RSVNG-103-HR-EPT	Croatia	15737068.5	20200607	14 Jan 2015
RSVNG-103-HU-EPT	Hungary	15737068.5	3094353	14 Jan 2015
RSVNG-103-IE-EPT	Ireland	15737068.5	3094353	14 Jan 2015
RSVNG-103-IS-EPT	Iceland	15737068.5	3094353	14 Jan 2015
RSVNG-103-IT-EPT	Italy	15737068.5	502020000050878	14 Jan 2015
RSVNG-103-JP-PCD	Japan	2020-020602		10 Feb 2020
RSVNG-103-JP-PCT	Japan	2016-541720	6836398	14 Jan 2015
RSVNG-103-KR-PCT	Republic of Korea	10-2016-7020393	2188437	14 Jan 2015
RSVNG-103-LT-EPT	Lithuania	15737068.5	3094353	14 Jan 2015
RSVNG-103-LU-EPT	Luxembourg	15737068.5	3094353	14 Jan 2015
RSVNG-103-LV-EPT	Latvia	15737068.5	3094353	14 Jan 2015
RSVNG-103-MC-EPT	Monaco	15737068.5	3094353	14 Jan 2015
RSVNG-103-MK-EPT	Macedonia	15737068.5	3094353	14 Jan 2015
RSVNG-103-MT-EPT	Malta	15737068.5	3094353	14 Jan 2015
RSVNG-103-MX-PCT	Mexico	MX/a/2016/008639	374517	14 Jan 2015
RSVNG-103-NL-EPT	Netherlands	15737068.5	3094353	14 Jan 2015
RSVNG-103-NO-EPT	Norway	15737068.5	3094353	14 Jan 2015
RSVNG-103-PL-EPT	Poland	15737068.5	3094353	14 Jan 2015
RSVNG-103-PT-EPT	Portugal	15737068.5	3094353	14 Jan 2015
RSVNG-103-RO-EPT	Romania	15737068.5	3094353	14 Jan 2015
RSVNG-103-RS-EPT	Serbia	15737068.5	60387	14 Jan 2015

RSVNG-103-RU-PCT	Russia	2016133247		14 Jan 2015
RSVNG-103-SE-EPT	Sweden	15737068.5	3094353	14 Jan 2015
RSVNG-103-SI-EPT	Slovenia	15737068.5	3094353	14 Jan 2015
RSVNG-103-SK-EPT	Slovakia	15737068.5	3094353	14 Jan 2015
RSVNG-103-SM-EPT	San Marino	15737068.5	SM-T-202000282	14 Jan 2015
RSVNG-103-TR-EPT	Turkey	15737068.5	3094353	14 Jan 2015
RSVNG-103-TW-NP	Taiwan	104101373	I705974	15 Jan 2015
RSVNG-103-US-CNT	USA	16/003,455	10,689,437	08 Jun 2018
RSVNG-103-US-CNT[2]	USA	16/864,454	11,186,628	01 May 2020
RSVNG-103-US-CNT[3]	USA	17/451,955		22 Oct 2021
RSVNG-103-US-PCT	USA	15/111,610		14 Jan 2015
RSVNG-103-WO-PCT	International	PCT/US2015/011391		14 Jan 2015

Priority Applications

AstraZeneca Case No:	Country	Application No.	Filing Date
RSVNG-103-US-PSP	USA	61/927,819	15 Jan 2014